FATE Fate Therapeutics Inc

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders.

$83.13  -5.36 (-6.06%)
As of 03/04/2021 15:59:53 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Mid cap
Health Care
Biotechnology
USA
USA
10/01/2013
87,244,032
885,221
$7,720,224,392
0.00%
SEC Edgar Online
10-Q
10-K
31189P102
US31189P1021
BCZS820

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
-44.53
20.19
245.60
-45.10%
-551.59%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy